TipRanks on MSN4d
Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges
Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call of ...
Corvus Pharmaceuticals reports Q4 EPS (18c), consensus (12c)
Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.
Corvus Pharmaceuticals price target raised to $15 from $14 at Oppenheimer
Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $15 from $14 and keeps an Outperform rating on the shares after ...